摘要
目的探讨乙酰半胱氨酸联合布地奈德雾化吸入治疗儿童肺炎的临床疗效。方法选取2018年6月至2019年5月在南华大学附属第一医院儿科就诊的肺炎患儿150例。采用随机数表法分为观察组和对照组,每组75例。对照组接受乙酰半胱氨酸雾化吸入治疗,观察组接受乙酰半胱氨酸联合布地奈德雾化吸入治疗治疗,两组均连续治疗1周。比较两组患儿的治疗效果、临床症状消失时间、治疗前后的白细胞介素-4(IL-4)、白细胞介素-3(IL-3)、C反应蛋白(CRP)水平,用力肺活量(FEV)、1 s用力呼气容积(FEV1)、最大呼气流量(PEF)的变化,以及不良反应发生情况。结果观察组患儿的治疗总有效率为90.63%,明显高于对照组的78.76%,差异有统计学意义(P<0.05);观察组患儿的咳嗽、发热、气促、肺部啰音等临床症状消失时间[(4.02±0.78)d、(2.45±0.55)d、(3.58±0.74)d、(5.25±0.85 d)]明显短于对照组[(5.53±0.95)d、(3.62±0.68)d、(4.69±0.86)d、(6.88±0.98)d],差异均具有统计学意义(P<0.05);治疗后,两组患儿的IL-4、IL-3及CRP水平均明显降低,且观察组[(4.52±0.78)pg/mL、(32.45±7.15)pg/mL、(16.23±3.12)mg/L]明显低于对照组[(5.88±0.89)pg/mL、(41.28±8.20)pg/mL、(19.24±3.28)mg/L],差异均具有统计学意义(P<0.05);观察组患儿治疗后的FEV、FEV1、PEF水平[(2.88±0.52)L、(72.12±10.12)%、(2.99±0.34)L/s]明显高于对照组[(2.41±0.4)L、(65.20±8.45)%、(2.67±0.32)L/s],差异均具有统计学意义(P<0.05);两组患儿均出现恶心、呕吐等不良反应,但两组患儿的不良反应发生率比较差异无统计学意义(P>0.05)。结论乙酰半胱氨酸联合布地奈德治疗肺炎患儿可有效改善患儿临床症状、肺功能,降低炎症因子表达水平,值得推广使用。
Objective To investigate the clinical efficacy of atomization inhalation with acetylcysteine and budesonide on children with pneumonia.Methods A total of 150 children with pneumonia were selected as subjects,who were admitted to the Department of Pediatrics at the First Affiliated Hospital of University of South China from June 2018 to May 2019.They were divided into observation group and control group,with 75 children in each group.The control group received atomization inhalation with acetylcysteine,and the observation group received atomization inhalation with acetylcysteine and budesonide;both groups were treated continuously for one week.The therapeutic effect,the disappearance time of clinical symptom,the levels of interleukin-4(IL-4),interleukin-3(IL-3)and C-reactive protein(CRP),the changes of forced expiratory volume(FEV),forced expiratory volume in 1 second(FEV1),and peak expiratory flow(PEF)were compared before and after treatment.Results The total effective rate of treatment was 90.63%in the observation group,which was significantly higher than 78.76%in the control group(P<0.05).The disappearance time of clinical symptoms were significantly shorter in the observation group than in the control group:cough,(4.02±0.78)days vs(5.53±0.95)days;fever,(2.45±0.55)days vs(3.62±0.68)days;shortness of breath,(3.58±0.74)days vs(4.69±0.86)days;lung rales,(5.25±0.85)days vs(6.88±0.98)days;all differences were statistically significant(P<0.05).After treatment,the levels of IL-4,IL-3 and CRP were significantly reduced in both groups,and the values were significantly lower in the observation group than in the control group:IL-4,(4.52±0.78)pg/mL vs(5.88±0.89)pg/mL;IL-3,(32.45±7.15)pg/mL vs(41.28±8.20)pg/mL;CRP,(16.23±3.12)mg/L vs(19.24±3.28)mg/L;all differences were statistically significant(P<0.05).After treatment,the levels of FEV,FEV1,PEF were significantly higher in the observation group than in the control group:FEV,(2.88±0.52)L vs(2.41±0.4)L;FEV1,(72.12±10.12)%vs(65.20±8.45)%;PEF,(2.99±0.34)L/s
作者
王维
罗永姣
WANG Wei;LUO Yong-jiao(Department of Pediatrics,the First Affiliated Hospital of University of South China,Hengyang 421001,Hunan,CHINA)
出处
《海南医学》
CAS
2019年第24期3213-3216,共4页
Hainan Medical Journal
关键词
肺炎
乙酰半胱氨酸
布地奈德
肺功能
炎症因子
疗效
Pneumonia
Acetylcysteine
Budesonide
Lung function
Inflammatory factors
Therapeutic effect
